中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents

The extreme reduction in cholinesterase caused by compound heterozygous mutations in the BCHE gene: A case report

DOI: 10.12449/JCH241023
Research funding:

Joint Logistics Support Force Scientific Research Project (LB20211A010024)

More Information
  • Corresponding author: YOU Shaoli, youshaoli1972@163.com (ORCID: 0000-0001-8689-8509)
  • Received Date: 2024-02-04
  • Accepted Date: 2024-03-01
  • Published Date: 2024-10-25
  • Serum cholinesterase (ChE) level is important for the diagnosis and prognostic evaluation of various diseases such as liver diseases and toxic diseases, and butyrylcholinesterase (BuChE) is an important component of ChE. Mutations in the BCHE gene can cause a significant reduction in the level of BuChE, with extensive reports in European and American populations and relatively few reports in Eastern countries, particularly China. This study describes a male patient, aged 35 years, who was misdiagnosed with organophosphorus pesticide poisoning due to an extreme reduction in ChE level and was given detoxification therapy, but such diagnosis was excluded by various biochemical examinations. Finally whole-exome sequencing and Sanger sequencing revealed the complex heterozygous mutations of c.1027dup and c.401dup at exon 2 of the BCHE gene, and hereditary BuChE deficiency due to these mutations is the cause of the extreme reduction in ChE level.

     

  • loading
  • [1]
    LOCKRIDGE O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses[J]. Pharmacol Ther, 2015, 148: 34- 46. DOI: 10.1016/j.pharmthera.2014.11.011.
    [2]
    ZHU GD, DAWSON E, HUSKEY A, et al. Genetic testing for BCHE variants identifies patients at risk of prolonged neuromuscular blockade in response to succinylcholine[J]. Pharmgenomics Pers Med, 2020, 13: 405- 414. DOI: 10.2147/PGPM.S263741.
    [3]
    IIDA S, KINOSHITA M, FUJII H, et al. Mutations of human butyrylcholinesterase gene in a family with hypocholinesterasemia[J]. Hum Mutat, 1995, 6( 4): 349- 351. DOI: 10.1002/humu.1380060411.
    [4]
    YEN T, NIGHTINGALE BN, BURNS JC, et al. Butyrylcholinesterase(BCHE) genotyping for post-succinylcholine apnea in an Australian population[J]. Clin Chem, 2003, 49( 8): 1297- 1308. DOI: 10.1373/49.8.1297.
    [5]
    YU RT, GUO YZ, DAN YJ, et al. A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: A case report[J]. BMC Med Genet, 2018, 19( 1): 58. DOI: 10.1186/s12881-018-0561-5.
    [6]
    MANOHARAN I, BOOPATHY R, DARVESH S, et al. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India[J]. Clin Chim Acta, 2007, 378( 1-2): 128- 135. DOI: 10.1016/j.cca.2006.11.005.
    [7]
    LOCKRIDGE O, NORGREN RB Jr, JOHNSON RC, et al. Naturally occurring genetic variants of human acetylcholinesterase and butyrylcholinesterase and their potential impact on the risk of toxicity from cholinesterase inhibitors[J]. Chem Res Toxicol, 2016, 29( 9): 1381- 1392. DOI: 10.1021/acs.chemrestox.6b00228.
    [8]
    NICOLET Y, LOCKRIDGE O, MASSON P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products[J]. J Biol Chem, 2003, 278( 42): 41141- 41147. DOI: 10.1074/jbc.M210241200.
    [9]
    AMMUNDSEN HB, SØRENSEN MK, GÄTKE MR. Succinylcholine resistance[J]. Br J Anaesth, 2015, 115( 6): 818- 821. DOI: 10.1093/bja/aev228.
    [10]
    WICHMANN S, FÆRK G, BUNDGAARD JR, et al. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene[J]. Pharmacogenet Genomics, 2016, 26( 7): 351- 356. DOI: 10.1097/FPC.0000000000000221.
    [11]
    ANDERSSON ML, MØLLER AM, WILDGAARD K. Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: A systematic review[J]. Anaesthesia, 2019, 74( 4): 518- 528. DOI: 10.1111/anae.14545.
    [12]
    BRIMIJOIN S, TYE S. Favorable impact on stress-related behaviors by modulating plasma butyrylcholinesterase[J]. Cell Mol Neurobiol, 2018, 38( 1): 7- 12. DOI: 10.1007/s10571-017-0523-z.
    [13]
    LI Q, YANG HY, CHEN Y, et al. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer’s disease[J]. Eur J Med Chem, 2017, 132: 294- 309. DOI: 10.1016/j.ejmech.2017.03.062.
    [14]
    SANTARPIA L, GRANDONE I, CONTALDO F, et al. Butyrylcholinesterase as a prognostic marker: A review of the literature[J]. J Cachexia Sarcopenia Muscle, 2013, 4( 1): 31- 39. DOI: 10.1007/s13539-012-0083-5.
    [15]
    SATO T, YAMAUCHI H, SUZUKI S, et al. Serum cholinesterase is an important prognostic factor in chronic heart failure[J]. Heart Vessels, 2015, 30( 2): 204- 210. DOI: 10.1007/s00380-014-0469-8.
    [16]
    GOLIASCH G, KLEBER ME, RICHTER B, et al. Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: The Vienna and Ludwigshafen Coronary Artery Disease(VILCAD) risk score[J]. Eur Heart J, 2012, 33( 18): 2282- 2289. DOI: 10.1093/eurheartj/ehs164.
    [17]
    YUAN M, HAN B, XIA YP, et al. Augmentation of peripheral lymphocyte-derived cholinergic activity in patients with acute ischemic stroke[J]. BMC Neurol, 2019, 19( 1): 236. DOI: 10.1186/s12883-019-1481-5.
    [18]
    GREMMEL T, WADOWSKI PP, MUELLER M, et al. Serum cholinesterase levels are associated with 2-year ischemic outcomes after angioplasty and stenting for peripheral artery disease[J]. J Endovasc Ther, 2016, 23( 5): 738- 743. DOI: 10.1177/1526602816655521.
    [19]
    FENG WM, TANG CW, GUO HH, et al. Prognostic value of serum cholinesterase activities in sepsis patients[J]. Hepatogastroenterology, 2013, 60( 125): 1001- 1005. DOI: 10.5754/hge13141.
    [20]
    ZIVKOVIC AR, TOURELLE KM, BRENNER T, et al. Reduced serum cholinesterase activity indicates splenic modulation of the sterile inflammation[J]. J Surg Res, 2017, 220: 275- 283. DOI: 10.1016/j.jss.2017.07.024.
    [21]
    KLOCKER EV, BARTH DA, RIEDL JM, et al. Decreased activity of circulating butyrylcholinesterase in blood is an independent prognostic marker in pancreatic cancer patients[J]. Cancers(Basel), 2020, 12( 5): 1154. DOI: 10.3390/cancers12051154.
    [22]
    YAMAMOTO M, SAITO H, UEJIMA C, et al. Combination of serum albumin and cholinesterase levels as prognostic indicator in patients ith colorectal cancer[J]. Anticancer Res, 2019, 39( 2): 1085- 1090. DOI: 10.21873/anticanres.13217.
    [23]
    SOUZA RL, MIKAMI LR, MAEGAWA RO, et al. Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample[J]. Mol Genet Metab, 2005, 84( 4): 349- 353. DOI: 10.1016/j.ymgme.2004.12.005.
    [24]
    ON-KEI CHAN A, LAM CW, TONG SF, et al. Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity[J]. Clin Chim Acta, 2005, 351( 1-2): 155- 159. DOI: 10.1016/j.cccn.2004.09.004.
    [25]
    LV HY, YANG LH, BU LN, et al. A case report of primary neonatal hypocholinesterase caused by homozygous frameshift mutation of the utyrylcholinesterase(BCHE) gene and review of literature[J]. Clin Lab, 2019, 65( 7). DOI: 10.7754/Clin.Lab.2019.181254.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (441) PDF downloads(18) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return